Nunzia Pharmaceutical Company
Nunzia Pharmaceutical Company
Your view on NUNZ
Overview
What the company does, where it operates, and who runs it.
About Nunzia Pharmaceutical Company
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Sara Gonzales
- Headquarters
- 1627 West 14th Street, Long Beach, CA, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Sara Gonzales
- Headquarters
- 1627 West 14th Street, Long Beach, CA, US
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com.
The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nunzia Pharmaceutical Company, and the rating behind it. NUNZ last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nunzia Pharmaceutical Company. Starting points for Nunzia Pharmaceutical Company: EPS -$0.26, beta -4.82 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nunzia Pharmaceutical Company. Nunzia Pharmaceutical Company does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nunzia Pharmaceutical Company. Trailing twelve-month EPS for Nunzia Pharmaceutical Company stands at -$0.26. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nunzia Pharmaceutical Company. Nunzia Pharmaceutical Company has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nunzia Pharmaceutical Company valued side by side against its closest peers. Nunzia Pharmaceutical Company is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nunzia Pharmaceutical Company, and how their positions are changing. At a $43,451 market value, institutional positions materially move Nunzia Pharmaceutical Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nunzia Pharmaceutical Company executives and directors. Shares of Nunzia Pharmaceutical Company have traded between $0.0001 and $0.0030 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nunzia Pharmaceutical Company. Nunzia Pharmaceutical Company is a $43,451 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nunzia Pharmaceutical Company. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nunzia Pharmaceutical Company. Coverage tracks Nunzia Pharmaceutical Company within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.